Mets' Cautious Approach with Adbert Alzolay: A Strategic Move
During a recent Mets broadcast, Gary Cohen shared insights on Adbert Alzolay's future with the team, revealing that the promising pitcher won't be making the roster this year. According to David Stearns, this decision is part of a careful strategy to manage Alzolay's recovery from Tommy John surgery.
A Calculated Recovery Plan
Alzolay, a savvy offseason acquisition, inked a two-year minor league deal with the Mets, fully aware that 2025 would be a year of rest and rehabilitation. The Mets are in no hurry to rush him back, prioritizing his long-term health and effectiveness over immediate contributions. This approach makes sense, especially for a reliever who was on the verge of becoming a high-leverage staple for the Cubs before his injury.
Depth and Development
With new additions like Craig Kimbrel and Luis Garcia, Alzolay’s path to the 26-man roster was always going to be challenging. The Mets seem committed to giving him the time he needs to fully recover, rather than risking an early return that could derail his progress. This minor league deal gives them flexibility, allowing Alzolay to hone his skills in Syracuse until he's truly ready.
Timing is Everything
The situation with Alzolay is reminiscent of Brooks Raley’s return last year, but with less urgency. Raley made his comeback mid-season, while Alzolay is being given a longer runway. The Mets are wisely avoiding the pitfalls of rushing a player back too soon, which could lead to losing him on waivers if things don't go as planned.
Looking Ahead
For now, Alzolay remains a part of the Mets’ future plans, waiting for the right moment to make his impact. His journey back to the majors will require patience and proof that he can outperform the competition. When the time is right, Alzolay could be a key piece in the Mets’ bullpen, but for now, the focus is on his recovery and development.